Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
8 VC Firms Certified for AMED Funding Project to Boost Pharma Ecosystem
The Japan Agency for Medical Research and Development (AMED) said on June 30 that it has selected eight companies as certified venture capitals under its funding project to boost the country’s drug discovery ecosystem. Under the project, AMED will provide…
To read the full story
Related Article
- Eisai and Taiho VC Firms Certified for AMED Startup Project
November 6, 2024
- AMED Selects 6 VCs for Biotech Startup Funding Project
February 21, 2024
- Mitsubishi Tanabe VC Firm Certified for AMED Startup Project
June 19, 2023
- JPMA Committed to Building Drug Discovery Ecosystem: President
July 5, 2022
- Japan to Boost Pharma Startup Ecosystem via VC Certification Program, Allocates 50 Billion Yen in FY2021 Extra Budget
December 15, 2021
REGULATORY
- AstraZeneca’s Oral SERD, MSD RSV Antibody Clear Japan Panel Review
May 26, 2026
- CEA Review Group Holds First Meeting, Technical Debate Yet to Begin
May 26, 2026
- US Calls Out Japan’s Market Expansion Re-Pricing Rules as “Unfair”: IP Report
May 26, 2026
- Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
May 25, 2026
- Ishin Deepens Debate on Healthcare Macroeconomic Indexing
May 25, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…